Liposome technology for cardiovascular disease treatment and diagnosis

Bibliography

• Knight CG. editors. Liposomes: from physical structure to theraputic applications. Elsevier North-Holland; Amsterdam: 1981
   Google Scholar
• New RR. editors. Liposomes: a practical approash. IRL Press at Oxford University Press; New York; 1990
   Google Scholar
• Afergan E, Ben David M, Epstein H, Liposomal simvastatin attenuates neointimal hyperplasia in rats. Aaps J 2010;12(2):181-7
   PubMed Web of Science ®Google Scholar
• Ma K, Shen HJ, Shen S, Development of a successive targeting liposome with multi-ligand for efficient targeting gene delivery. J Gene Med 2011;13(5):290-301
   PubMed Web of Science ®Google Scholar
• Okamura Y, Eto K, Maruyama H, Visualization of liposomes carrying fibrinogen gamma-chain dodecapeptide accumulated to sites of vascular injury using computed tomography. Nanomedicine 2010;6(2):391-6
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4(2):145-60
   PubMed Web of Science ®Google Scholar
• Woodle MC. Controlling liposome blood clearance by surface-grafted polymers. Adv Drug Deliv Rev 1998;32(1-2):139-52
   PubMed Web of Science ®Google Scholar
• Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009;30(11):592-9
   PubMed Web of Science ®Google Scholar
• Mccarthy JR. Multifunctional agents for concurrent imaging and therapy in cardiovascular disease. Adv Drug Deliv Rev 2010;62(11):1023-30
   PubMed Web of Science ®Google Scholar
• Juliano RL, Stamp D. Effect of particle-size and charge on clearance rates of liposomes and liposome encapsulated drugs. Biochem Biophys Res Commun 1975;63(3):651-8
   PubMed Web of Science ®Google Scholar
• Caride VJ, Zaret BL. Liposome accumulation in regions of experimental myocardial-infarction. Science 1977;198(4318):735-8
   PubMed Web of Science ®Google Scholar
• Kaufmann BA, Sanders JM, Davis C, Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation 2007;116(3):276-84
   PubMed Web of Science ®Google Scholar
• Palmer TN, Caride VJ, Caldecourt MA, The mechanism of liposome accumulation in infarction. Biochim Biophys Acta 1984;797(3):363-8
   PubMed Web of Science ®Google Scholar
• Khaw BA, Torchilin VP, Vural I, Plug and seal - prevention of hypoxic cardiocyte death by sealing membrane lesions with antimyosin-liposomes. Nat Med 1995;1(11):1195-8
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Narula J, Halpern E, Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. Biochim Biophys Acta 1996;1279(1):75-83
   PubMed Web of Science ®Google Scholar
• Monkkonen J, Valjakka R, Hakasalo M, The Effects of liposome surface-charge and size on the intracellular delivery of clodronate and gallium in-vitro. Int J Pharm 1994;107(3):189-97
   Google Scholar
• Monkkonen J, Liukkonen J, Taskinen M, Studies on liposome formulations for intraarticular delivery of clodronate. J Control Release 1995;35(2-3):145-54
   Web of Science ®Google Scholar
• Bally MB, Dos Santos N, Allen C, Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta 2007;1768(6):1367-77
   PubMed Web of Science ®Google Scholar
• Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006;1(3):297-315
   PubMed Web of Science ®Google Scholar
• Lestini BJ, Sagnella SM, Xu Z, Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. J Control Release 2002;78(1-3):235-47
   PubMed Web of Science ®Google Scholar
• Gregoriadis G, Neerunjun ED. Homing of liposomes to target-cells. Biochem Biophys Res Commun 1975;65(2):537-44
   PubMed Web of Science ®Google Scholar
• Gao J, Liu W, Xia Y, The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials 2011;32(13):3459-70
   PubMed Web of Science ®Google Scholar
• Scott RC, Rosano JM, Ivanov Z, Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function. FASEB J 2009;23(10):3361-7
   PubMed Web of Science ®Google Scholar
• Braunwald E, Libby P, Bonow R, editors. Braunwald's heart disease: a textbook of cardiovascular medicine. 8th edition. Sauders Elsevier; Philadelphia: 2008
   Google Scholar
• Elbayoumi TA, Torchilin VP. Liposomes for targeted delivery of antithrombotic drugs. Expert Opin Drug Deliv 2008;5(11):1185-98
   PubMed Web of Science ®Google Scholar
• Lim SJ, Kang DI, Lee S, Preparation and in vitro evaluation of anti-VCAM-1-Fab″-conjugated liposomes for the targeted delivery of the poorly water-soluble drug celecoxib. J Microencapsul 2011;28(3):220-7
   PubMed Web of Science ®Google Scholar
• Homem De Bittencourt PI Jr, Lagranha DJ, Maslinkiewicz A, LipoCardium: endothelium-directed cyclopentenone prostaglandin-based liposome formulation that completely reverses atherosclerotic lesions. Atherosclerosis 2007;193(2):245-58
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Khaw BA, Smirnov VN, Preservation of Antimyosin antibody-activity after covalent coupling to liposomes. Biochem Biophys Res Commun 1979;89(4):1114-19
   PubMed Web of Science ®Google Scholar
• Khaw BA, Narula J, Vural I, Cytoskeleton-specific immunoliposomes: sealing of hypoxic cells and intracellular delivery of DNA. Int J Pharm 1998;162(1-2):71-6
   Web of Science ®Google Scholar
• Khaw BA, Dasilva J, Hartner WC. Cytoskeletal-antigen specific immunoliposome-targeted in vivo preservation of myocardial viability. J Control Release 2007;120(1-2):35-40
   PubMed Web of Science ®Google Scholar
• Scott RC, Crabbe D, Krynska B, Aiming for the heart: targeted delivery of drugs to diseased cardiac tissue. Expert Opin Drug Deliv 2008;5(4):459-70
   PubMed Web of Science ®Google Scholar
• Takahama H, Minamino T, Asanuma H, Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats. J Am Coll Cardiol 2009;53(8):709-17
   PubMed Web of Science ®Google Scholar
• Maciel NR, Reis PG, Kato KC, Reduced cardiovascular alterations of tartar emetic administered in long-circulating liposomes in rats. Toxicol Lett 2010;199(3):234-8
   PubMed Web of Science ®Google Scholar
• Gabizon AA, Barenholz Y, Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid - pharmacokinetic studies in rodents and dogs. Pharm Res 1993;10(5):703-8
   PubMed Web of Science ®Google Scholar
• Gabizon A, Horowitz AT, Goren D, In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res 2003;9(17):6551-9
   PubMed Web of Science ®Google Scholar
• Kaminskas LM, Mcleod VM, Kelly BD, A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. Nanomedicine 2011
   Web of Science ®Google Scholar
• Doggrell SA. Statins in the 21st century: end of the simple story? Expert Opin Investig Drugs 2001;10(9):1755-66
   PubMed Web of Science ®Google Scholar
• Assmus B, Urbich C, Aicher A, HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 2003;92(9):1049-55
   PubMed Web of Science ®Google Scholar
• Nusca A, Melfi R, Di Sciascio G. Percutaneous coronary interventions and statins therapy. Ther Adv Cardiovasc Dis 2008;2(2):101-7
   PubMedGoogle Scholar
• Aso S, Ise H, Takahashi M, Effective uptake of N-acetylglucosamine-conjugated liposomes by cardiomyocytes in vitro. J Control Release 2007;122(2):189-98
   PubMed Web of Science ®Google Scholar
• Csempesz F, Sule A, Puskas I. Induced surface activity of supramolecular cyclodextrin-statin complexes: relevance in drug delivery. Colloids Surf A 2010;354(1-3):308-13
   Web of Science ®Google Scholar
• Levchenko TS, Hartner WC, Verma DD, ATP-loaded liposomes for targeted treatment in models of myocardial ischemia. Methods Mol Biol 2010;605:361-75
   PubMedGoogle Scholar
• Hartner WC, Verma DD, Levchenko TS, ATP-loaded liposomes for treatment of myocardial ischemia. Wires Nanomed Nanobiotechnol 2009;1(5):530-9
   PubMed Web of Science ®Google Scholar
• Xu GX, Xie XH, Liu FY, Adenosine-triphosphate liposomes - encapsulation and distribution studies. Pharm Res 1990;7(5):553-7
   PubMed Web of Science ®Google Scholar
• Liang W, Levchenko T, Khaw BA, ATP-containing immunoliposomes specific for cardiac myosin. Curr Drug Deliv 2004;1(1):1-7
   PubMedGoogle Scholar
• Verma DD, Hartner WC, Levchenko TS, ATP-loaded liposomes effectively protect the myocardium in rabbits with an acute experimental myocardial infarction. Pharm Res 2005;22(12):2115-20
   PubMed Web of Science ®Google Scholar
• Verma DD, Levchenko TS, Bernstein EA, ATP-loaded liposomes effectively protect mechanical functions of the myocardium from global ischemia in an isolated rat heart model. J Control Release 2005;108(2-3):460-71
   PubMed Web of Science ®Google Scholar
• Verma DD, Levchenko TS, Bernstein EA, ATP-loaded immunoliposomes specific for cardiac myosin provide improved protection of the mechanical functions of myocardium from global ischemia in an isolated rat heart model. J Drug Target 2006;14(5):273-80
   PubMed Web of Science ®Google Scholar
• Watts N. Bisphosphonates, statins, osteoporosis, and atherosclerosis. South Med J 2002;95(6):578-82
   PubMed Web of Science ®Google Scholar
• Moreau MF, Guillet C, Massin P, Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. Biochem Pharmacol 2007;73(5):718-23
   PubMed Web of Science ®Google Scholar
• Yu B, Wu L, Zhu L, Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells. Eur J Pharmacol 2009;602(1):124-31
   PubMed Web of Science ®Google Scholar
• Shi WH, Wu L, Zhu L, Zoledronate inhibits intimal hyperplasia in balloon-injured rat carotid artery. Eur J Vasc Endovasc Surg 2011;41(2):288-93
   PubMed Web of Science ®Google Scholar
• Damrauer SM, Fisher MD, Wada H, A20 inhibits post-angioplasty restenosis by blocking macrophage trafficking and decreasing adventitial neovascularization. Atherosclerosis 2010;211(2):404-8
   PubMed Web of Science ®Google Scholar
• Danenberg HD, Fishbein I, Gao JC, Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation 2002;106(5):599-605
   PubMed Web of Science ®Google Scholar
• Ylitalo R, Monkkonen J, Yla-Herttuala S. Effects of liposome-encapsulated bisphosphonates on acetylated LDL metabolism, lipid accumulation and viability of phagocyting cells. Life Sci 1997;62(5):413-22
   Web of Science ®Google Scholar
• Danenberg HD, Golomb G, Groothuis A, Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation 2003;108(22):2798-804
   PubMed Web of Science ®Google Scholar
• Epstein H, Gutman D, Cohen-Sela E, Preparation of alendronate liposomes for enhanced stability and bioactivity: in vitro and in vivo characterization. Aaps J 2008;10(4):505-15
   PubMed Web of Science ®Google Scholar
• Biorest Liposomal Alendronate With Stenting sTudy (BLAST). ClinicalTrialsgov Available from: http://clinicaltrials.gov/ct2/show/NCT00739466 [Cited 2010]
   Google Scholar
• BIOrest LABR-312 may BLAST through as new anti-inflammatory therapy. Available from: http://www.cmio.net/index.php?option=com_articles&article=24254&topic=24 [Cited 22 November 2011]
   Google Scholar
• Theoharis S, Manunta M, Tan PH. Gene delivery to vascular endothelium using chemical vectors: implications for cardiovascular gene therapy. Expert Opin Biol Ther 2007;7(5):627-43
   PubMed Web of Science ®Google Scholar
• Baker AH. Designing gene delivery vectors for cardiovascular gene therapy. Prog Biophys Mol Biol 2004;84(2-3):279-99
   PubMed Web of Science ®Google Scholar
• Lavu M, Gundewar S, Lefer DJ. Gene therapy for ischemic heart disease. J Mol Cell Cardiol 2011;50(5):742-50
   PubMed Web of Science ®Google Scholar
• Khurana R, Shafi S, Martin J, Vascular endothelial growth factor gene transfer inhibits neointimal macrophage accumulation in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 2004;24(6):1074-80
   PubMed Web of Science ®Google Scholar
• Abegunewardene N, Schmidt KH, Vosseler M, Local transient myocardial liposomal gene transfer of inducible nitric oxide synthase does not aggravate myocardial function and fibrosis and leads to moderate neovascularization in chronic myocardial ischemia in pigs. Microcirculation 2010;17(1):69-78
   PubMed Web of Science ®Google Scholar
• Hedman M, Hartikainen J, Syvanne M, Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia - Phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003;107(21):2677-83
   PubMed Web of Science ®Google Scholar
• Von Der Leyen HE, Mugge A, Hanefeld C, A prospective, single-blind, multicenter, Dose Escalation study of Intracoronary iNOS Lipoplex (CAR-MP583) Gene therapy for the prevention of restenosis in patients with de novo or Restenotic Coronary Artery Lesion (REGENT I Extension). Hum Gene Ther 2011;22:1-8
   Google Scholar
• Hinkel R, Trenkwalder T, Kupatt C. Gene therapy for ischemic heart disease. Expert Opin Biol Ther 2011;11(6):723-37
   PubMed Web of Science ®Google Scholar
• Kaneda Y, Saeki Y, Morishita R. Gene therapy using HVJ-liposomes: the best of both worlds? Mol Med Today 1999;5(7):298-303
   PubMedGoogle Scholar
• Ellison KE, Bishopric NH, Webster KA, Fusigenic liposome-mediated DNA transfer into cardiac myocytes. J Mol Cell Cardiol 1996;28(7):1385-99
   PubMed Web of Science ®Google Scholar
• Yin XH, Yutani C, Ikeda Y, Tissue factor pathway inhibitor gene delivery using HVJ-AVE liposomes markedly reduces restenosis in atherosclerotic arteries. Cardiovasc Res 2002;56(3):454-63
   PubMed Web of Science ®Google Scholar
• Yin X, Fu Y, Yutani C, HVJ-AVE liposome-mediated Tissue Factor Pathway Inhibitor (TFPI) gene transfer with recombinant TFPI (rTFPI) irrigation attenuates restenosis in atherosclerotic arteries. Int J Cardiol 2009;135(2):245-8
   PubMed Web of Science ®Google Scholar
• Sakurai H, Kawabata K, Sakurai F, Innate immune response induced by gene delivery vectors. Int J Pharm 2008;354(1-2):9-15
   PubMed Web of Science ®Google Scholar
• Leuschner F, Nahrendorf M. Molecular imaging of coronary atherosclerosis and myocardial infarction: considerations for the bench and perspectives for the clinic. Circ Res 2011;108(5):593-606
   PubMed Web of Science ®Google Scholar
• Lipinski MJ, Amirbekian V, Frias JC, MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med 2006;56(3):601-10
   PubMed Web of Science ®Google Scholar
• Hamilton AJ, Huang SL, Warnick D, Intravascular ultrasound molecular Imaging of atheroma components in vivo. J Am Coll Cardiol 2004;43(3):453-60
   PubMed Web of Science ®Google Scholar
• Lipinski MJ, Frias JC, Amirbekian V, Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis. JACC Cardiovasc Imaging 2009;2(5):637-47
   PubMed Web of Science ®Google Scholar
• Eraso LH, Reilly MP, Sehgal C, Emerging diagnostic and therapeutic molecular imaging applications in vascular disease. Vasc Med 2011;16(2):145-56
   PubMed Web of Science ®Google Scholar
• Meaney JFM, Goyen M. Recent advances in contrast-enhanced magnetic resonance angiography. Eur Radiol 2007;17:B2-6
   PubMed Web of Science ®Google Scholar
• Kaul S, Lindner JR. Visualizing coronary atherosclerosis in vivo: thinking big, imaging small. J Am Coll Cardiol 2004;43(3):461-3
   PubMed Web of Science ®Google Scholar
• Ayyagari AL, Zhang XD, Ghaghada KB, Long-circulating liposomal contrast agents for magnetic resonance imaging. Magn Reson Med 2006;55(5):1023-9
   PubMed Web of Science ®Google Scholar
• Annapragada AV, Ghaghada KB, Bockhorst KHJ, High-resolution vascular imaging of the rat spine using liposomal blood pool MR agent. AJNR Am J Neuroradiol 2007;28(1):48-53
   PubMed Web of Science ®Google Scholar
• Maiseyeu A, Mihai G, Kampfrath T, Gadolinium-containing phosphatidylserine liposomes for molecular imaging of atherosclerosis. J Lipid Res 2009;50(11):2157-63
   PubMed Web of Science ®Google Scholar
• Conyers JL, Danila D, Partha R, Antibody-labeled liposomes for CT imaging of atherosclerotic plaques in vitro investigation of an Anti-ICAM antibody-labeled liposome containing iohexol for molecular imaging of atherosclerotic plaques via computed tomography. Tex Heart Inst J 2009;36(5):393-403
   PubMed Web of Science ®Google Scholar
• Allen C, Zheng JZ, Liu JB, In vivo performance of a liposomal vascular contrast agent for CT and MR-based image guidance applications. Pharm Res 2007;24(6):1193-201
   PubMed Web of Science ®Google Scholar
• Kluza E, van der Schaft DWJ, Hautvast PA, Synergistic targeting of alpha(v)beta(3) integrin and Galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett 2010;10(1):52-8
   PubMed Web of Science ®Google Scholar
• Lanza GM, Wickline SA. Targeted ultrasonic contrast agents for molecular imaging and therapy. Prog Cardiovasc Dis 2001;44(1):13-31
   PubMed Web of Science ®Google Scholar
• Smith DA, Porter TM, Martinez J, Destruction thresholds of echogenic liposomes with clinical diagnostic ultrasound. Ultrasound Med Biol 2007;33(5):797-809
   PubMed Web of Science ®Google Scholar
• Huang SL, Hamilton AJ, Nagaraj A, Improving ultrasound reflectivity and stability of echogenic liposomal dispersions for use as targeted ultrasound contrast agents. J Pharm Sci 2001;90(12):1917-26
   PubMed Web of Science ®Google Scholar
• Demos SM, Alkan-Onyuksel H, Kane BJ, In vivo targeting of acoustically reflective liposomes for intravascular and transvascular ultrasonic enhancement. J Am Coll Cardiol 1999;33(3):867-75
   PubMed Web of Science ®Google Scholar
• Hagisawa K, Nishioka T, Suzuki R, Enhancement of ultrasonic thrombus imaging using novel liposomal bubbles targeting activated platelet glycoprotein IIb/IIIa complex-in vitro and in vivo study. Int J Cardiol 2010;152:202-6
   PubMed Web of Science ®Google Scholar
• Herbst SM, Klegerman ME, Kim H, Delivery of stem cells to porcine arterial wall with echogenic liposomes conjugated to antibodies against CD34 and intercellular adhesion molecule-1. Mol Pharm 2010;7(1):3-11
   PubMedGoogle Scholar
• Yang CS, Tai LA, Wang YC. Heat-activated sustaining nitric oxide release from zwitterionic diazeniumdiolate loaded in thermo-sensitive liposomes. Nitric Oxide 2010;23(1):60-4
   PubMed Web of Science ®Google Scholar
• Laing ST, Kim H, Kopechek JA, Ultrasound-mediated delivery of echogenic immunoliposomes to porcine vascular smooth muscle cells in vivo. J Liposome Res 2010;20(2):160-7
   PubMed Web of Science ®Google Scholar
• Schroeder A, Kost J, Barenholz Y. Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes. Chem Phys Lipids 2009;162(1-2):1-16
   PubMed Web of Science ®Google Scholar
• Buchanan KD, Huang SL, Kim H, Encapsulation of NF-kappaB decoy oligonucleotides within echogenic liposomes and ultrasound-triggered release. J Control Release 2010;141(2):193-8
   PubMed Web of Science ®Google Scholar
• Newman CM, Lawrie A, Brisken AF, Ultrasound gene therapy: on the road from concept to reality. Echocardiography 2001;18(4):339-47
   PubMed Web of Science ®Google Scholar
• Laing ST, Moody M, Smulevitz B, Ultrasound-enhanced thrombolytic effect of tissue plasminogen activator-loaded echogenic liposomes in an in vivo rabbit aorta thrombus model. Arterioscler Thromb Vasc Biol 2011;31:1357-9
   PubMed Web of Science ®Google Scholar
• Szebeni J, Muggia F, Gabizon A, Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 2011;63(12):1020-30
   PubMed Web of Science ®Google Scholar
• Laye C, Mcclements DJ, Weiss J. Formation of biopolymer-coated liposomes by electrostatic deposition of chitosan. J Food Sci 2008;73(5):N7-N15
   PubMed Web of Science ®Google Scholar
• Scarioti GD, Lubambo A, Feitosa JPA, Nanocapsule of cationic liposomes obtained using “in situ” acrylic acid polymerization: Stability, surface charge and biocompatibility. Colloids Surf B 2011;87(2):267-72
   PubMed Web of Science ®Google Scholar
• Preat V, Danhier F, Feron O. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010;148(2):135-46
   PubMed Web of Science ®Google Scholar
• Sharif F, Hynes SO, Mccullagh KJ, Gene-eluting stents: non-viral, liposome-based gene delivery of eNOS to the blood vessel wall in vivo results in enhanced endothelialization but does not reduce restenosis in a hypercholesterolemic model. Gene Ther June 2011. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Centis V, Proulx P, Vermette P. PEGylated liposomes encapsulating human hemoglobin enhance oxygen transfer and cell proliferation while decreasing cell hypoxia in fibrin. Biochem Eng J 2011;55(3):162-8
   Web of Science ®Google Scholar
• Gunawan RC, Auguste DT. The role of antibody synergy and membrane fluidity in the vascular targeting of immunoliposomes. Biomaterials 2010;31(5):900-7
   PubMed Web of Science ®Google Scholar
• Auguste DT, Gunawan RC. Immunoliposomes that target endothelium in vitro are dependent on lipid raft formation. Mol Pharm 2010;7(5):1569-75
   PubMedGoogle Scholar
• Hamilton A, Huang SL, Warnick D, Left ventricular thrombus enhancement after intravenous injection of echogenic immunoliposomes - Studies in a new experimental model. Circulation 2002;105(23):2772-8
   PubMed Web of Science ®Google Scholar
• Haber E, Afergan E, Epstein H, Route of administration-dependent anti-inflammatory effect of liposomal alendronate. J Control Release 2010;148(2):226-33
   PubMed Web of Science ®Google Scholar
• Huang SL, Kee PH, Kim H, Nitric oxide-loaded echogenic liposomes for nitric oxide delivery and inhibition of intimal hyperplasia. J Am Coll Cardiol 2009;54(7):652-9
   PubMed Web of Science ®Google Scholar
• Leach JK, O'rear EA, Patterson E, Accelerated thrombolysis in a rabbit model of carotid artery thrombosis with liposome-encapsulated and microencapsulated streptokinase. Thromb Haemost 2003;90(1):64-70
   PubMed Web of Science ®Google Scholar
• Joner M, Morimoto K, Kasukawa H, Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma. Arterioscler Thromb Vasc Biol 2008;28(11):1960-U113
   PubMed Web of Science ®Google Scholar
• Mcewan JR, Meng QH, Jamal W, Application to vascular adventitia of a nonviral vector for TIMP-1 gene therapy to prevent intimal hyperplasia. Hum Gene Ther 2006;17(7):717-27
   PubMed Web of Science ®Google Scholar
• Pfosser A, Thalgott M, Buttner K, Liposomal Hsp90 cDNA induces neovascularization via nitric oxide in chronic ischemia. Cardiovasc Res 2005;65(3):728-36
   PubMed Web of Science ®Google Scholar
• Pelisek J, Fuchs A, Engelmann MG, Vascular endothelial growth factor response in porcine coronary and peripheral arteries using nonsurgical occlusion model, local delivery, and liposome-mediated gene transfer. Endothelium 2003;10(4-5):247-55
   PubMed Web of Science ®Google Scholar